APLTNasdaqdelisted

Applied Therapeutics, Inc.

Healthcare·Oncology·Phase 3·New York, NY, United States
OncologyRare DiseaseNeurologyOphthalmologyCardiovascularInfectious DiseaseRespiratoryMusculoskeletal

Applied Therapeutics, Inc. (APLT): 12 pipeline candidates · ~3 mo cash runway · 10 clinical trials. Updated within the last hour.

7.3/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway0.8

2.9 months

Financial Health9.9

D/E -62.27 · 1% dilution

Pipeline Maturity8.5

Lead: Phase 3

Pipeline Breadth10.0

12 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for Applied Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$14.9M

Cash

$11.9M

Quarterly Burn

$18.4M

Runway

2.9 mo

Revenue

$1.0M

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Sep 2026
Today~7 mo out
Catalyst within runway

Pipeline (12 candidates)

Showing 10 of 12 candidates. Sign up for full pipeline.

10 clinical trials·4 FDA decisions·CEO: Interim Chief Executive

Frequently asked questions

How many drug candidates are in Applied Therapeutics, Inc.'s pipeline?

Applied Therapeutics, Inc. (APLT) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Applied Therapeutics, Inc.'s lead drug candidate?

Applied Therapeutics, Inc.'s most advanced tracked candidate is AT-001 (caficrestat) (Phase 3) for Treatment of diabetic cardiomyopathy (DbCM).

What is Applied Therapeutics, Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Applied Therapeutics, Inc. has approximately 2.9 months of cash runway.

What is Applied Therapeutics, Inc.'s market capitalization?

Applied Therapeutics, Inc.'s market capitalization is approximately $14.9M.

Who is the CEO of Applied Therapeutics, Inc.?

Interim Chief Executive is the chief executive officer of Applied Therapeutics, Inc. (APLT).

Get the full picture on Applied Therapeutics, Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.